Mazdutide
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
Innovent · Phase 1/2 · Completed · Enrollment 60
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| IBI362 | n/r | n/r | n/r | n/r | n/r |
| placebo | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.